Pursuant to the letter of intent, Mistral will issue common shares from treasury to the shareholders of US Pharma Co. in exchange for 100% of the equity securities of US Pharma Co.
The Transaction is expected to constitute a reverse take over of Mistral as defined in the policies of the TSX Venture Exchange (the “TSX-V”). As a result, the Transaction will be subject to Mistral shareholder approval and a special meeting of shareholders will be convened shortly after a definitive agreement is entered into. Mistral will also consider a consolidation of its outstanding shares.

As soon as the due diligence process is completed and the negotiations regarding the conclusion of a definitive agreement have been finalized, a more detailed press release will be issued describing the terms of the proposed transaction and its related conditions